Dose-response analyses of momelotinib (CYT387), a JAK1 and JAK2 inhibitor, from a phase I/II study (CCL09101) in treatment of myelofibrosis

Authors
Category Primary study
JournalBlood
Year 2013
This article has no abstract
Epistemonikos ID: 2d7ae23f1488bf4c4dfb17185c2fa127dc4adc63
First added on: Feb 05, 2025